2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-14873
    Tonapofylline 340021-17-2 ≥98.0%
    Tonapofylline (BG 9928) is an orally active and selective adenosine A1 receptor antagonist with a Ki of 7.4 nM for human adenosine A1 receptor (hA1), which displays 915-fold selectivity versus human adenosine A2A receptor and 12-fold selectivity versus human adenosine A2B receptor and is used in development for the treatment of heart failure.
    Tonapofylline
  • HY-15035
    S-Diclofenac 912758-00-0 99.20%
    S-Diclofenac (ACS 15) is a hybrid molecule of an H2S donor and the NSAID diclofenac. S-Diclofenac activates the p53 signaling pathway, and inhibits the activation of JNK. S-Diclofenac exhibits antioxidant and anti-inflammatory activities.
    S-Diclofenac
  • HY-15378
    Talibegron hydrochloride 178600-17-4 99.63%
    Talibegron hydrochloride (ZD2079 hydrochloride) is a potent β3-adrenoceptor agonist with a pD2 of 3.72 on phenylephrine-preconstricted rat mesenteric artery. Talibegron hydrochloride has potent vasorelaxant effect.
    Talibegron hydrochloride
  • HY-18965
    TAS-301 193620-69-8 99.61%
    TAS-301 is an inhibitor of smooth muscle cell migration and proliferation, and inhibits PKC activation induced by PDGF.
    TAS-301
  • HY-19026
    Siguazodan 115344-47-3 99.06%
    Siguazodan (SKF 94836) is a potent, selective and orally active phosphodiesterase III (PDE-III) inhibitor with an IC50 of 117 nM. Siguazodan increases cAMP accumulation in intact platelets with an EC50 of 18.88 μM. Siguazodan also inhibits phenylephrine-induced 5-HT release with an IC50 value of 4.2 μM.
    Siguazodan
  • HY-19406
    AE-3763 291778-77-3 99.82%
    AE-3763 is a peptide-based human neutrophil elastase inhibitor with an IC50 of 29 nM.
    AE-3763
  • HY-19666
    DPI 201-106 97730-95-5 99.49%
    DPI 201-106 (SDZ 201106) is a cardiotonic agent with a synergistic sarcolemmal and intracellular mechanism of action. DPI 201-106 shows cardioselective modulation of voltage-gated sodium channels (VGSCs) resulting in a positive inotropic effect.
    DPI 201-106
  • HY-69055
    7-Bromoisoquinoline 58794-09-5 ≥98.0%
    7-Bromoisoquinoline is a drug intermediate that can be used for the synthesis of Cortistatin A.
    7-Bromoisoquinoline
  • HY-77734
    AR-C133913XX 1251765-07-7 ≥98.0%
    AR-C124910XX is a metabolite of Ticagrelor (HY-10064 ). Ticagrelor is a reversible oral P2Y12 receptor antagonist, and can be used for study of platelet aggregation.
    AR-C133913XX
  • HY-A0199
    Sodium tetradecyl sulfate (27% in water) 139-88-8
    Sodium tetradecyl sulfate (Tergitol 4) is a novel scleroembolic agent and an apoptosis inducer. Sodium tetradecyl sulfate can be used for research on varicose veins and vascular malformation diseases.
    Sodium tetradecyl sulfate (27% in water)
  • HY-A0275
    Amezinium methylsulfate 30578-37-1 99.72%
    Amezinium metilsulfate has multiple mechanisms, including stimulation of alpha and beta-1 receptors and inhibition ofnoradrenaline and tyramine uptake.
    Amezinium methylsulfate
  • HY-B1181
    Hydrastinine hydrochloride 4884-68-8 99.41%
    Hydrastinine hydrochloride is a major alkaloid constituent in goldenseal (Hydrastis canadensis). Hydrastinine hydrochloride can be used as a haemostatic agent.
    Hydrastinine hydrochloride
  • HY-N0518
    Toddalolactone 483-90-9 99.97%
    Toddalolactone, a main component of Toddalia asiatica, inhibits the activity of recombinant human plasminogen activator inhibitor-1 (PAI-1), with an IC50 value of 37.31 μM.
    Toddalolactone
  • HY-N0833
    L-Hisidine (monohydrocholoride) 645-35-2
    L-Hisidine is an essential amino acid for infants. L-Hisidine is an inhibitor of mitochondrial glutamine transport.
    L-Hisidine (monohydrocholoride)
  • HY-N1403
    Tigogenin 77-60-1 98.0%
    Tigogenin is a steroidal sapogenins. Tigogenin can inhibit adipocytic differentiation and induce osteoblastic differentiation in mouse bone marrow stromal cells. Tigogenin can inhibit cells proliferation and induce apoptosis. Tigogenin can be used for the researches of cancer, inflammation, immunology, metabolic and cardiovascular disease, such as mammary gland carcinoma, rheumatoid arthritis, osteoporosis and atherosclerosis.
    Tigogenin
  • HY-N1923
    Hypaconine 63238-68-6 99.0%
    Hypaconine is a C19-diterpenoid alkaloid isolated from Aconitum and Delphinium spp. Hypaconine exhibits strong cardiac activity.
    Hypaconine
  • HY-N2107
    Physion 8-O-β-D-glucoside 26296-54-8 98.0%
    Physion 8-O-β-D-glucoside, a bioactive component of Fallopia multiflora, can be used for the research of dizziness.
    Physion 8-O-β-D-glucoside
  • HY-N2299
    Morusinol 62949-93-3 99.68%
    Morusinol is a flavonoid isolated from Morus alba root bark. Morusinol has an antiplatelet activity and  significantly inhibits arterial thrombosis in vivo.
    Morusinol
  • HY-N2509
    Iristectorigenin B 86849-77-6 99.49%
    Iristectorigenin B (Iristectrigenin B) is a liver X receptor (LXR) modulator. Iristectrigenin B stimulates the transcriptional activity of both LXR-α and LXR-β.
    Iristectorigenin B
  • HY-N2929
    β-Hydroxypropiovanillone 2196-18-1
    β-Hydroxypropiovanillone, a natural compound, shows significant concentration-dependent inhibitory effects on α-glucosidase with an IC50 of 257.8 μg/mL.
    β-Hydroxypropiovanillone
Cat. No. Product Name / Synonyms Application Reactivity